Código QR (código de barras bidimensional)

Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis

Abstract Background For children aged 6–11 years with uncontrolled severe atopic dermatitis (AD), 16 weeks of treatment with dupilumab resulted in substantial clinical benefit compared with placebo with an acceptable safety profile. However, longer-term safety and efficacy data are important to info...

Fuld beskrivelse

Na minha lista:
Principais autores: Michael J. Cork, Diamant Thaçi, Lawrence F. Eichenfield, Peter D. Arkwright, Zhen Chen, Ryan B. Thomas, Matthew P. Kosloski, Ariane Dubost-Brama, Randy Prescilla, Ashish Bansal, Noah A. Levit
Format: Artigo
Sprog:Inglês
Udgivet: Adis, Springer Healthcare 2023-09-01
Serier:Dermatology and Therapy
Fag:
Atopic dermatitis
Children
Dupilumab
Eczema
Efficacy
Long-term
Online adgang:https://doi.org/10.1007/s13555-023-01016-9
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker